Evidence strength in FDA premarket approval of cardiovascular devices.

摘要

To the Editor: In their systematic review, Dr Dhruva and colleagues1 examined studies supporting premarket approval (PMA) of cardiovascular devices by the US Food and Drug Administration (FDA). They concluded that the FDA often uses studies that lack adequate strength as the basis for device approvals.